%PDF-1.4
%
81 0 obj
<>
endobj
78 0 obj
<>
endobj
153 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T15:29:49Z
2024-03-28T13:42:38-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T13:42:38-07:00
application/pdf
Heather
2001-465.april02
uuid:bb8a3f1f-1dd1-11b2-0a00-1d0a27bd7700
uuid:bb8a3f22-1dd1-11b2-0a00-900000000000
endstream
endobj
65 0 obj
<>
endobj
67 0 obj
<>
endobj
66 0 obj
<>
endobj
68 0 obj
<>
endobj
58 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
154 0 obj
[159 0 R]
endobj
155 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.0228 Tw 8 0 0 8 54 714.5293 Tm
[(Rosa, CA; K. Kolba, Nap, Santa Maria CA; J.S. )17.8 (T)69.7 (oder)39.7 (, Nap, Johnston, RI;)]TJ
0.02341 Tw 0 -1.2375 TD
[(D. McLain, Nap, Birmingham, )54.8 (AL; J. Kaine, Nap, Sarasota, FL; J. )54.8 (Aelion,)]TJ
0.00369 Tc 0.3712 Tw T*
[(Nap, Jackson, )17.7 (TN; M. )54.8 (Abeles Univ)64.9 (. of Connecticut Health Center)39.7 (,)]TJ
-0.00011 Tc 0.0648 Tw T*
[(Farmington, CT)54.8 (; )54.7 (A. Fraser)39.7 (, Graves-Gilbert Clinic; Bowling Green, KY)91.7 (; J.)]TJ
-0.01041 Tw T*
[(T)69.7 (esser)39.7 (, Nap, Phoenix, )54.9 (AZ; O. Lawless, Center for )54.9 (Arthritis, Immunology &)]TJ
0.02499 Tw T*
[(Env)64.8 (. Disorders, Olney)64.8 (, MD; )17.7 (W)91.7 (.)-0.1 ( St. Clair)39.7 (, Due Hospital, Durham, NC.)]TJ
/TT1 1 Tf
0 Tw 10 0 0 10 54 641.0293 Tm
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.02499 Tw 8 0 0 8 61 631.0293 Tm
[(1.)-875 (Maini R, St. Clair EW)91.8 (, Breedveld F)79.8 (, et al. Infliximab \(chimeric)]TJ
1.675 -1.25 Td
(anti-tumour necrosis factor alpha monoclonal antibody\) versus)Tj
0 -1.25 TD
(placebo in rheumatoid arthritis patients receiving concomitant)Tj
T*
[(methotrexate: a randomised phase III trial. )54.9 (A)111.1 (TTRACT)-257.2 (Study)]TJ
T*
(Group. Lancet 1999;354:1932-9.)Tj
-1.675 -1.25 Td
[(2.)-875 (Lipsky P)110.8 (, St. Clair )17.7 (W)91.8 (, Furst D, et al. 54-week clinical and )]TJ
-0.00011 Tc 1.675 -1.25 Td
[(radiographic results from the )54.8 (A)111 (TTRACT)-257.3 (trial: )54.8 (A)-219.9 (phase I trial.)]TJ
0 Tc T*
(Arthritis Rheum 1999;42 Suppl:S401.)Tj
-1.675 -1.25 Td
[(3.)-875 (Lipsky P)110.8 (, van der Heijde D, St. Clair )17.7 (W)91.8 (, et al. 102-wk clinical &)]TJ
1.675 -1.25 Td
[(radiologic results from the )54.8 (A)111.1 (TTRACT)-257.2 (trial: )54.8 (A)-219.8 (2 year)39.8 (, randomized,)]TJ
T*
(controlled, phase 3 trial of infliximab \(Remicade\256\) in patients wit\
h)Tj
T*
[(active RA)-220.1 (despite MTX [abstract]. )54.8 (Arthritis Rheum 2000;43)]TJ
0 Tw T*
(Suppl:S269.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Scallon B, Cai )54.8 (A, Shealy D, Solowksi N, Song X, )17.7 (W)79.7 (agner C. New)]TJ
1.675 -1.25 Td
[(comparisons of two types of )17.7 (TNF-a antagonists approved for)]TJ
T*
[(rheumatoid arthritis [abstract]. )54.8 (Arthritis Rheum 2000;43 Suppl.)]TJ
0 Tc -1.675 -1.25 Td
[(5.)-875 (Maini RN, )17.7 (T)69.8 (aylor PC. )54.8 (Anti-cytokine therapy for rheumatoid)]TJ
1.675 -1.25 Td
[(arthritis. )54.9 (Ann Rev Med 2000;51:207-29.)]TJ
-1.675 -1.25 Td
[(6.)-875 (Guidelines for the management of rheumatoid arthritis. )54.9 (American)]TJ
1.675 -1.25 Td
(College of Rheumatology ad hoc committee on clinical guidelines.)Tj
T*
(Arthritis Rheum 1996;39:713-22.)Tj
31.325 35.4375 Td
[(7.)-875 (W)79.8 (olfe F)79.8 (, Cathey M. )17.7 (The assessment and prediction of functional)]TJ
1.675 -1.25 Td
(disability in rheumatoid arthritis. J Rheumatol 1991;18:1298-306.)Tj
-1.675 -1.25 Td
[(8.)-875 (Kippel JH. Biologic therapy for rheumatoid arthritis. N Engl J Med)]TJ
0 Tw 1.675 -1.25 Td
(2000;343:1640-1.)Tj
0.0249 Tw -1.675 -1.25 Td
[(9.)-875 (Bathon J, Martin R, Fleischmann R, et al. )54.8 (A)-219.8 (comparison of )]TJ
1.675 -1.25 Td
(etanercept and methotrexate in patients with early rheumatoid)Tj
T*
(arthritis. N Engl J Med 2000;343:1586-93.)Tj
-2.175 -1.25 Td
[(10.)-875 (Knight DM, )17.7 (T)34.9 (rinh H, Le J, et al. Construction and initial )]TJ
2.175 -1.25 Td
[(characterization of a mouse-human chimeric anti-TNF antibody)64.9 (.)]TJ
T*
(Mol Immunol 1993;30:1443-53.)Tj
-0.00011 Tc -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Scallon BJ, Moore MA, )17.7 (T)34.8 (rinh H, Knight DM, Ghrayeb J. Chimeric)]TJ
0 Tc 2.1381 -1.25 Td
(anti-TNF-alpha monoclonal antibody cA2 binds recombinant )Tj
T*
[(transmembrane )17.7 (TNF-alpha and activates immune ef)17.8 (fector func-)]TJ
T*
(tions. Cytokine 1995;7:251-9.)Tj
-2.175 -1.25 Td
[(12.)-875 (Schaible )17.7 (TF)79.8 (. Long term safety of infliximab. Can J Gastroenterol-)]TJ
-0.00011 Tc 2.175 -1.25 Td
(Update on Liver and Inflammatory Bowel Disease \(ULIBD\))Tj
0 Tc 0 Tw T*
(2000;14:29-32C.)Tj
0.0249 Tw -2.175 -1.25 Td
[(13.)-875 (T)69.8 (a)0.2 (r)17.8 (gan SR, Hanauer SB, van Deventer SJ, et al. )54.8 (A)-219.8 (short-term study)]TJ
2.175 -1.25 Td
(of chimeric monoclonal antibody cA2 to tumor necrosis factor)Tj
-0.00011 Tc T*
[(alpha for Crohn\222)54.8 (s disease. Crohn\222)54.8 (s Disease cA2 Study Group. N)]TJ
0 Tc T*
(Engl J Med 1997;337:1029-35.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Camussi G, Lupia E. )17.7 (The future role of anti-tumor necrosis factor)]TJ
2.175 -1.25 Td
(\(TNF\) products in the treatment of rheumatoid arthritis. Drugs)Tj
0 Tc 0 Tw T*
(1998;55:613-20.)Tj
0.0249 Tw -2.175 -1.25 Td
[(15.)-875 (Maini RN, Breedveld FC, Kalden JR, et al. )17.7 (Therapeutic ef)17.8 (ficacy of)]TJ
2.175 -1.25 Td
(multiple intravenous infusions of anti-tumor necrosis factor alpha)Tj
T*
(monoclonal antibody combined with low-dose weekly methotrexate)Tj
T*
[(in rheumatoid arthritis [see comments]. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1998;41:1552-63.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT2 1 Tf
0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Sher)36.9 (gy)54.9 (, et al: Infliximab in RA)]TJ
0 Tw 61.4375 -0.0313 Td
(677)Tj
ET
0 0 0 0 scn
/GS0 gs
102.15 57.55 407.5 -10.83 re
f*
0.5 w
102.15 57.55 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
130 0 obj
<>
endobj
158 0 obj
<>
endobj
90 0 obj
<>
endobj
61 0 obj
<>
endobj
84 0 obj
<>
endobj
86 0 obj
<>
endobj
118 0 obj
<>stream
HV pUBBr@6d7 $\ $1C GE0j*˲j aYMJ٥ZpYcc) *",0_OVmm|v1/dO`N
+}z)Zڱ8m@Y匊3#PsոW D=K%ۯmfWNA!|t\&P-cׁRFTU7t{W/OʹZ0[_9_v2!JDx
U$+;XgKIZqWшHE.F= +hwqlq{lG9.^l@%
igV?^b4N3v:ơ du=OTZHϢ*jpc0#uaV3pT=N2/'ڄ0X E@$za2ϚOb8
㌘**VS"B wiuXMA[JhHBWƝeFfp\!"_,*neKҺZw{لQ\gL;=GW' oD^b16I8ekXI{kaN+]}uZa|qWp14o ճGƳg?K%)1!s\lLtOuj.m0CS)5r}3cp~
?L'mL2ӟвgK#K w5th7Ic^cfsh=*VSBL;2.=to\yn
5s^_5
zw::okG6_RɶFltJ_b-$\EtSdMiȦ3td3>N ՍQK(1JM_do!͌5rW.=f[4er4Ҭlο܈tƔˋ
Mu
%RkK|t3ffXq]=MԼz`|2K09
O=z'5],Y{{=t-mE~roې݁G{T5a1g^@T2L3iƧH3l_ j]S-9?m4o<)JQ?^~t`6T)emHHם^e&QR!u
`].e=NƬ[똞"Slއ[SPg4W,Kyi[>1C]Z4 CpkpGX<¬5!Ջ}`_T|erM8Ցc!+ (@ŜW,mO*&Œ$)4)>ujȷ>s2.!6A{*o-`/feuHzuZ8[P`.c$-ܕ]Yv=2+Qd?b)O亀\m~*,;w7c!E"#JuGmqx$}aN!-~A6FO_&cl伉ԉT!b*O㿬WL[;?l0`hg `~C0!
AX~# I3ॲ#M2mdtdcin ,ceYQiMj[f&?*{A&FSV7DW!C(2+HQ8E}`;g8'ZR
A
8̷4SfY> 6+K,;(e4r˵O 1 oug{ IBP)>m;q=X=,=6t}5!&cxPr2,oY$rrW,~>?w3ޟ|wN7Z<
z71;[,N%DCuT#/ŀCD$mmdzh:L&&dN{$itL:&CD#*p42S 9 ` id U#' $<gi8Y# &|c F0h(^#G 4r 95r idXM#fV/އDQ7rmµpIiό
w! _废5u@ˀ8 ]~1 "(akj;iC*:pa"NEPmPMPJA*(%
ZǤߏI?
Ǥ1I7/!e8*~9`